ArticleCurrent medicinal chemistry2026
Exploring the Anticancer Potential of
Article in Current medicinal chemistry, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLaunaea mucronata has garnered the interest of chemists, particularly in the field of oncology. While not traditionally used for cancer treatment, studies have shown that its methanolic extract exhibits cytotoxic effects against human cancer cell lines.
methodsHerein, thirty-three metabolites were spotted in the aqueous extract of Launaea mucronata via UPLC-MS/MS, primarily flavonoids, hydroxycinnamic acid derivatives, and carboxylic acid derivatives. The extract's antiproliferative activity was tested on HCT-116 (colon), MCF7 (breast), and HePG2 (liver) cancer cells, showing notable potency. A molecular docking study assessed the extract's bioactive compounds for their binding to human DNA-Topo II enzyme complexes. Molecular dynamics simulations (200 ns) were performed on the top-scoring complexes (dicaffeoyl-succinoylquinic acid 7, tricaffeoyl quinic acid 10, feruloyl-O-p-coumaroyl-O-caffeoylshikimic acid 12, and kaempferol-rutinoside 23) using Schrödinger's Desmond package. Binding stability was further validated by MM-GBSA energy calculations via Schrödinger's thermal_mmgbsa. py script.
resultsThe IC DISCUSSION: A total of 33 metabolites of Launaea mucronata identified via UPLC-MS/ MS were identified as promising anticancer candidates against both HePG2 and MCF7 cell lines. Additionally, their mechanisms of action involve DNA intercalation and inhibition of topoisomerase II (Topo II) through molecular docking, molecular dynamics, and MM-GBSA calculations.
conclusionThese findings highlight Launaea mucronata's promising anticancer potential, supported by both experimental and computational evidence.
Indexed as
Identifiers
42099141What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.